HUMAN CD63 FULL LENGTH PROTEIN

Cat.#: 12233
Product Name: Human CD63 Full Length Protein
Size : 10 µg, 50 µg and 100 µg
Synonyms: LAMP-3; ME491; MLA1; OMA81H; TSPAN30
Target: CD63
UNIPROT ID: P08962
Description: Human CD63 full length protein membrane nanoparticles (MNPs)
Background: The protein is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. The encoded protein is a cell surface glycoprotein that is known to complex with integrins. It may function as a blood platelet activation marker. Deficiency of this protein is associated with Hermansky-Pudlak syndrome. Also this gene has been associated with tumor progression. Alternative splicing results in multiple transcript variants encoding different protein isoforms.
Species/Host: HEK293
Molecular Weight: The human full length CD63 protein has a MW of 25.6 kDa
Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization.
Storage & Shipping: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.



Figure1. Elisa plates were pre-coated with 0.5 μg/per well purified human CD63 full length membrane nanoparticles. Serial diluted anti-CD63 monoclonal antibody (28219) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CD63 monoclonal antibody binding with CD63 full length membrane nanoparticles is 61.65ng/ml.



Figure2. FACS analysis of CD63 MNPs A. Negative Control 1: CD63 full length membrane nanoparticles samples were stained only with Goat anti-human IgG 488 secondary antibody. B. Negative Control 2: Control membrane nanoparticles samples were stained with anti-CD63 antibody (28219) at 2μg/ml, followed by Goat anti-human IgG 488 secondary antibody. C. Negative Control 3: CD63 full length membrane nanoparticles samples were stained with anti-GPRC5D antibody (an irrelevant antibody) at 2μg/ml, followed by Goat anti-human IgG 488 secondary antibody. D. CD63 full length membrane nanoparticles samples were stained with anti-CD63 antibody (28219) at 2μg/ml, followed by Goat anti-human IgG 488 secondary antibody.